Literature DB >> 2842034

Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone.

C H Dunphy1, A G Ayala, D A Swanson, J Y Ro, C Logothetis.   

Abstract

This study of 93 patients with Stage I nonseminomatous and mixed germ cell testicular tumors who were placed in a surveillance study following orchiectomy was designed to evaluate pathologic prognostic factors. Follow-up was at least 12 months post-orchiectomy except for one patient who was followed for 9 months. Lymphatic invasion was identified in 26 patients, 62% of whom developed distant metastases; metastasis developed in only 18% of 67 patients without lymphatic invasion (P less than 0.01). Relapse was also associated with the presence of embryonal carcinoma. Of 81 patients with an embryonal carcinoma component, 35% developed metastases, whereas none of those without an embryonal carcinoma developed metastasis (P = 0.05). Effects of other histologic features and tumor size were not significant. Lymphatic invasion appeared to be a significant poor prognostic factor, and embryonal carcinoma was an independent poor prognostic factor.

Entities:  

Mesh:

Year:  1988        PMID: 2842034     DOI: 10.1002/1097-0142(19880915)62:6<1202::aid-cncr2820620627>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.

Authors:  C Bokemeyer; M A Kuczyk; J Serth; J T Hartmann; H J Schmoll; U Jonas; L Kanz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors.

Authors:  J Baniel; B J Roth; R S Foster; J P Donohue
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

3.  Adult primary teratoma of the testis--report on 5 cases in clinical stage I disease.

Authors:  A B Porcaro; S Z Antoniolli; G Martignoni; M Brunelli; P Curti
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

4.  Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists.

Authors:  Daniel M Berney; Ferran Algaba; Mahul Amin; Brett Delahunt; Eva Compérat; Jonathan I Epstein; Peter Humphrey; Mohammed Idrees; Antonio Lopez-Beltran; Cristina Magi-Galluzzi; Gregor Mikuz; Rodolfo Montironi; Esther Oliva; John Srigley; Victor E Reuter; Kiril Trpkov; Thomas M Ulbright; Murali Varma; Clare Verrill; Robert H Young; Ming Zhou; Lars Egevad
Journal:  Histopathology       Date:  2015-03-17       Impact factor: 5.087

5.  Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.

Authors:  Soner Guney; Nese Guney; Nurettin Cem Sonmez; Erbil Ergenekon
Journal:  Med Oncol       Date:  2008-09-26       Impact factor: 3.064

6.  Prognostic features and markers for testicular cancer management.

Authors:  Eddy S Leman; Mark L Gonzalgo
Journal:  Indian J Urol       Date:  2010 Jan-Mar

7.  How safe is surveillance in patients with histologically low-risk non-seminomatous testicular cancer in a geographically extended country with limited computerised tomographic resources?

Authors:  S D Fosså; A B Jacobsen; N Aass; A Heilo; A E Stenwig; O Kummen; N B Johannessen; G Waaler; P Ogreid; L Borge
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

Review 8.  Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis.

Authors:  Joost M Blok; Ilse Pluim; Gedske Daugaard; Thomas Wagner; Katarzyna Jóźwiak; Erica A Wilthagen; Leendert H J Looijenga; Richard P Meijer; J L H Ruud Bosch; Simon Horenblas
Journal:  BJU Int       Date:  2020-01-08       Impact factor: 5.588

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.